Viking Therapeutics: Analysts See High Potential Despite Stock Decline

Viking Therapeutics Inc. (NASDAQ: VKTX) closed on August 24, 2026 at 28.95 US dollars (approximately 26.10 Swiss francs or 24.80 euros) – unchanged from the previous day. During the day, the California-based biotech company's stock moved between 28.80 and 29.45 US dollars.

Analyst Consensus: Broad Buy Recommendation Despite Volatile Developments

The analyst assessment is clear-cut: Of 24 covered analysts, 23 issue a buy or strong buy recommendation, with only one rating as hold (as of July 9, 2026). The average price target is 93.60 US dollars, the median target at 95 US dollars. The range of estimates spans from 83 to 101 US dollars – even the most conservative target is thus nearly 190 percent above the current price.

Investment bank BTIG Research reaffirmed its buy recommendation for Viking Therapeutics on August 17, 2026, when the stock was trading at 34.36 US dollars. Since then, however, the price has continued to decline.

Price Decline in July: Weaker Than Competitors

In July 2026, the VKTX stock lost 15 percent, performing significantly worse than competitors in the GLP-1 therapy space – a class of agents for treating diabetes and obesity. For comparison: Structure Therapeutics (GPCR) fell 8 percent, Eli Lilly (LLY) 2 percent, and Altimmune (ALT) 1 percent. Companies such as Novo Nordisk, Amgen, Terns Pharmaceuticals, and Regeneron recorded positive developments during the same period.

The Relative Strength Index (RSI) stood at 47.93 on August 21, 2026 – a neutral value that indicates neither overbought nor oversold conditions.

Pipeline Progress and Clinical Data in Focus

Viking Therapeutics develops novel therapies for metabolic and endocrine diseases. The company is in the pre-revenue phase – it does not yet generate revenues from approved products. The focus is on dual-GLP-1/GIP receptor agonists, a promising drug class in the growing market for obesity and diabetes therapies.

In the second quarter of 2026, Viking Therapeutics recorded EBITDA growth of minus 149.2 percent – a metric that for clinical-stage companies primarily reflects ongoing research and development costs. Loss per share (EPS) is minus 4.66 US dollars on an annualized basis.

Market Capitalization and Valuation

With a market capitalization of approximately 3.8 billion US dollars (around 3.4 billion Swiss francs), Viking Therapeutics ranks among mid-size biotech stocks. The price-to-book ratio (P/B ratio) stands at 6.22. A traditional price-to-earnings ratio (P/E) is not available due to absent profits.

The stock exhibits a beta of 0.61 – it thus historically fluctuates around 40 percent less than the overall market. The stock's 52-week high was marked at 43.15 US dollars, the low at 22.96 US dollars. From the current price, the distance to the year-high is around 33 percent.

Classification for DACH Investors

For investors in the German-speaking region, a typical biotech constellation emerges: A company without revenues but with a clinical pipeline in an attractive market segment. The broad analyst consensus and high price targets reflect expectations for successful clinical trials and possible approvals. At the same time, risk remains high – typical for biotech stocks in early development phases.

The relative underperformance in July 2026 compared to established competitors such as Eli Lilly and Novo Nordisk demonstrates the higher volatility of smaller biotech stocks. Currency risks for euro and franc investors come into play, as the stock is denominated in US dollars.

Average trading volume stands at approximately 1.76 million shares – a level that offers adequate liquidity for retail investors. On August 24, 2026, however, only around 5,800 shares were traded, a significantly below-average volume indicating low market interest on that trading day.